MAP2K7 and melanoma: COMBI-AD [70,71] evaluated the efficacy of adjuvant targeted therapies, dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) combination therapy in patients with stage III melanoma and BRAF V600 mutation.